Find Naloxegol Oxalate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF DossiersDRUG PRODUCT COMPOSITIONS

145RELATED EXCIPIENT COMPANIES

245EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1354744-91-4, Nktr-118 oxalate, Naloxegol (oxalate), Naloxegol oxalate [usan], Az13337019 oxalate, Az-13337019 oxalate
Molecular Formula
C36H55NO15
Molecular Weight
741.8  g/mol
InChI Key
MNYIRXLCPODKLG-VUTNLTPYSA-N
FDA UNII
65I14TNM33

Naloxegol Oxalate
1 2D Structure

Naloxegol Oxalate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;oxalic acid
2.1.2 InChI
InChI=1S/C34H53NO11.C2H2O4/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2;3-1(4)2(5)6/h3-5,28-29,32,36-37H,1,6-25H2,2H3;(H,3,4)(H,5,6)/t28-,29+,32-,33-,34+;/m0./s1
2.1.3 InChI Key
MNYIRXLCPODKLG-VUTNLTPYSA-N
2.1.4 Canonical SMILES
COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O.C(=O)(C(=O)O)O
2.1.5 Isomeric SMILES
COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O.C(=O)(C(=O)O)O
2.2 Other Identifiers
2.2.1 UNII
65I14TNM33
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1354744-91-4

2. Nktr-118 Oxalate

3. Naloxegol (oxalate)

4. Naloxegol Oxalate [usan]

5. Az13337019 Oxalate

6. Az-13337019 Oxalate

7. 65i14tnm33

8. Moventig

9. (4r,4as,7s,7ar,12bs)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;oxalic Acid

10. Naloxegol Oxalate (usan)

11. Unii-65i14tnm33

12. Movantik (tn)

13. Moventig (tn)

14. Nktr-118-oxalate

15. Naloxegol Oxalate [mi]

16. Naloxegol Oxalate(nktr-118)

17. Chembl2219416

18. Schembl20839999

19. Hy-a0118a

20. Dtxsid50159395

21. Naloxegol Oxalate [who-dd]

22. Akos030526444

23. Cs-5349

24. Naloxegol Oxalate [orange Book]

25. Nktr-118;az-13337019 Oxalate

26. Ac-36031

27. Movantik Component Naloxegol Oxalate

28. Az 13337019

29. Naloxegol Oxalate Component Of Movantik

30. D10375

31. Q27263878

32. 4,5.alpha.-epoxy-6.alpha.-((3,6,7,12,15,18,21-heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol Hydrogen Ethanedioate

33. 4,5alpha-epoxy-6alpha-((3,6,7,12,15,18,21-heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol Hydrogen Ethanedioate

34. Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5.alpha.,6.alpha.)-, Ethanedioate (1:1)

35. Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5alpha,6alpha)-, Ethanedioate (1:1)

2.4 Create Date
2012-05-14
3 Chemical and Physical Properties
Molecular Weight 741.8 g/mol
Molecular Formula C36H55NO15
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count16
Rotatable Bond Count25
Exact Mass741.35717005 g/mol
Monoisotopic Mass741.35717005 g/mol
Topological Polar Surface Area201 Ų
Heavy Atom Count52
Formal Charge0
Complexity971
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Pharmacological Classes
Opioid Antagonists [MoA]; Opioid Antagonist [EPC]
5.2 ATC Code

A06AH03


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663785000,"product":"MSN LIFE, NALOXEGOL OXALATE (AS PER INVO","address":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD","city":"HYDERABAD TS","supplier":"MSN LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"UNDISCLOSED","customerCountry":"CANADA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"50000","totalValueFC":"146841.1","currency":"USD","unitRateINR":3922666.6666666665,"date":"22-Sep-2022","totalValueINR":"11768000","totalValueInUsd":"146841.1","indian_port":"HYDERABAD AIR","hs_no":"29391900","bill_no":"4348084","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE,PLOT NO.C-24,INDUSTRIAL E SANATH NAGAR,HYDERABAD, HYDERABAD TS","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698172200,"product":"NALOXEGOL OXALATE (NX)","address":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL","city":"HYDERABAD, AP","supplier":"MSN LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"50000","totalValueFC":"9792.2","currency":"USD","unitRateINR":4075000,"date":"25-Oct-2023","totalValueINR":"815000","totalValueInUsd":"9792.2","indian_port":"Hyderabad Air","hs_no":"29391900","bill_no":"4872678","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728066600,"product":"NALOXEGOL OXALATE (NX)","address":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL","city":"HYDERABAD, AP","supplier":"MSN LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"HAMPTON PHARMA LLC","customerCountry":"UNITED STATES","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"48750","totalValueFC":"289055.7","currency":"USD","unitRateINR":4048059.6666666665,"date":"05-Oct-2024","totalValueINR":"24288358","totalValueInUsd":"289055.7","indian_port":"Hyderabad Air","hs_no":"29391900","bill_no":"4596977","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL, HYDERABAD, AP","customerAddress":""}]
22-Sep-2022
05-Oct-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Movantik

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Grunenthal

Deal Size: $250.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition July 22, 2024

blank

01

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.

Product Name : Movantik

Product Type : Controlled Substance

Upfront Cash : Undisclosed

July 22, 2024

blank

Details:

MOVANTIK is the leading Peripherally-Acting Mu-Receptor Opioid antagonist (PAMORA) indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Movantik

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: HCR

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 14, 2022

blank

02

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : MOVANTIK is the leading Peripherally-Acting Mu-Receptor Opioid antagonist (PAMORA) indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior canc...

Product Name : Movantik

Product Type : Controlled Substance

Upfront Cash : Undisclosed

November 14, 2022

blank

Details:

Under the terms of the settlement agreement, Apotex may not sell a generic version of Movantik in the U.S. until October 1, 2030 (subject to U.S. FDA approval) or earlier under certain circumstances.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Movantik

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Apotex Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 22, 2021

blank

03

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Under the terms of the settlement agreement, Apotex may not sell a generic version of Movantik in the U.S. until October 1, 2030 (subject to U.S. FDA approval) or earlier under certain circumstances.

Product Name : Movantik

Product Type : Controlled Substance

Upfront Cash : Undisclosed

July 22, 2021

blank

Details:

Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placebo were evaluated across high and low opioid dosages.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Movantik

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 09, 2021

blank

04

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placebo were evaluated across high and low opioid dosages.

Product Name : Movantik

Product Type : Controlled Substance

Upfront Cash : Inapplicable

July 09, 2021

blank

Details:

Both analyses included pooled data from two large, robust, identically designed Phase 3 studies of Movantik (Kodiak 4 and Kodiak 5), involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 546 patients in the placebo arms.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Movantik

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 24, 2021

blank

05

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Both analyses included pooled data from two large, robust, identically designed Phase 3 studies of Movantik (Kodiak 4 and Kodiak 5), involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 546 patients in the placebo a...

Product Name : Movantik

Product Type : Controlled Substance

Upfront Cash : Inapplicable

May 24, 2021

blank

Details:

The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Movantik

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: RedHill Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership February 18, 2021

blank

06

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.

Product Name : Movantik

Product Type : Controlled Substance

Upfront Cash : Undisclosed

February 18, 2021

blank

Details:

RedHill Biopharma has gained the rights to Movantik (naloxegol)1 in Israel from AstraZeneca. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. RedHill to evaluate partnering opportunities for commercialization of Movantik in Israel.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Moventig

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: RedHill Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 10, 2020

blank

07

AstraZeneca

United Kingdom
arrow
AGGSpend
Not Confirmed

AstraZeneca

United Kingdom
arrow
AGGSpend
Not Confirmed

Details : RedHill Biopharma has gained the rights to Movantik (naloxegol)1 in Israel from AstraZeneca. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. RedHill to evaluate partnering opportunities for commercialization of Movantik i...

Product Name : Moventig

Product Type : Controlled Substance

Upfront Cash : Undisclosed

August 10, 2020

blank

Details:

RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik® with a new royalty-bearing agreement, under which RedHill will maintain sole and exclusive responsibility for the commercialization of Movantik® in the U.S.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Movantik

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: RedHill Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 08, 2020

blank

08

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik® with a new royalty-bearing agreement, under which RedHill will maintain sole and exclusive responsibility for the commercialization of Movantik® in the U.S.

Product Name : Movantik

Product Type : Controlled Substance

Upfront Cash : Undisclosed

March 08, 2020

blank

Details:

In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.


Lead Product(s): Naloxegol Oxalate

Therapeutic Area: Gastroenterology Brand Name: Moventig

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: RedHill Biopharma

Deal Size: $67.5 million Upfront Cash: $52.5 million

Deal Type: Divestment February 04, 2020

blank

09

AstraZeneca

United Kingdom
arrow
AGGSpend
Not Confirmed

AstraZeneca

United Kingdom
arrow
AGGSpend
Not Confirmed

Details : In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.

Product Name : Moventig

Product Type : Controlled Substance

Upfront Cash : $52.5 million

February 04, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

AstraZeneca AB

United Kingdom
AGGSpend
Not Confirmed
arrow

AstraZeneca AB

United Kingdom
arrow
AGGSpend
Not Confirmed

naloxegoloxalat

Brand Name : Moventig

Dosage Form : FILMDRAGERAD TABLETT

Dosage Strength : 25 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

02

AstraZeneca AB

United Kingdom
AGGSpend
Not Confirmed
arrow

AstraZeneca AB

United Kingdom
arrow
AGGSpend
Not Confirmed

naloxegoloxalat

Brand Name : Moventig

Dosage Form : FILMDRAGERAD TABLETT

Dosage Strength : 12,5 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

03

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

naloxegol

Brand Name : Moventig

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 12.5 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

naloxegol

Brand Name : Moventig

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 12.5 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

05

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

naloxegol

Brand Name : Moventig

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 25 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

06

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

naloxegol

Brand Name : Moventig

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 25 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

07

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

naloxegol

Brand Name : Moventig

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 25 mg

Packaging : Blister, endose

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

08

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

naloxegol

Brand Name : Moventig

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 25 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

09

Cederberg GmbH

Country
AGGSpend
Not Confirmed
arrow

Cederberg GmbH

Country
arrow
AGGSpend
Not Confirmed

Naloxegolum

Brand Name : Moventig

Dosage Form : Filmtable

Dosage Strength : 12.5mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

10

Cederberg GmbH

Country
AGGSpend
Not Confirmed
arrow

Cederberg GmbH

Country
arrow
AGGSpend
Not Confirmed

Naloxegolum

Brand Name : Moventig

Dosage Form : Filmtable

Dosage Strength : 25mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - EQ 12.5MG BASE

USFDA APPLICATION NUMBER - 204760

read-more

DOSAGE - TABLET;ORAL - EQ 25MG BASE

USFDA APPLICATION NUMBER - 204760

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Controlled & Modified Release

read-more
read-more

Taste Masking

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Granulation

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Rheology Modifiers

read-more
read-more

Coloring Agents

read-more
read-more

Parenteral

read-more
read-more

Empty Capsules

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Solubilizers

read-more
read-more

Emulsifying Agents

read-more
read-more

Topical

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
AGGSpend
Not Confirmed
arrow
AGGSpend
Not Confirmed

Company : Redhill/Valinor

Naloxegol Oxalate

Drug Cost (USD) : 113,804,302

Year : 2023

Prescribers : 64628

Prescriptions : 241878

blank

02

arrow
AGGSpend
Not Confirmed
arrow
AGGSpend
Not Confirmed

Company : Valinor Pharma

Naloxegol Oxalate

Drug Cost (USD) : 26,792,552

Year : 2023

Prescribers : 31553

Prescriptions : 55213

blank

03

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Company : Astrazeneca

Naloxegol Oxalate

Drug Cost (USD) : 1,493,075

Year : 2022

Prescribers : 1671

Prescriptions : 3897

blank

04

arrow
AGGSpend
Not Confirmed
arrow
AGGSpend
Not Confirmed

Company : Redhill Biophar

Naloxegol Oxalate

Drug Cost (USD) : 121,381,425

Year : 2022

Prescribers : 64510

Prescriptions : 262366

blank

05

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Company : Astrazeneca

Naloxegol Oxalate

Drug Cost (USD) : 6,119,564

Year : 2021

Prescribers : 7877

Prescriptions : 16040

blank

06

arrow
AGGSpend
Not Confirmed
arrow
AGGSpend
Not Confirmed

Company : Redhill Biophar

Naloxegol Oxalate

Drug Cost (USD) : 93,535,593

Year : 2021

Prescribers : 52574

Prescriptions : 216628

blank

07

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Company : Astrazeneca

Naloxegol Oxalate

Drug Cost (USD) : 80,887,806

Year : 2020

Prescribers : 48900

Prescriptions : 200061

blank

08

arrow
AGGSpend
Not Confirmed
arrow
AGGSpend
Not Confirmed

Company : Redhill Biophar

Naloxegol Oxalate

Drug Cost (USD) : 12,413,099

Year : 2020

Prescribers : 18691

Prescriptions : 29102

blank

09

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Company : Astrazeneca

Naloxegol Oxalate

Drug Cost (USD) : 93,313,255

Year : 2019

Prescribers : 56370

Prescriptions : 236107

blank

10

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Brand Name : Movantik

United Kingdom
arrow
AGGSpend
Not Confirmed

Company : Astrazeneca

Naloxegol Oxalate

Drug Cost (USD) : 86,783,013

Year : 2018

Prescribers : 57820

Prescriptions : 231111

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Regulatory FDF Prices

read-more
read-more

01

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 12.5 mg

Price Per Pack (Euro) : 89.738

Published in :

Country : Norway

RX/OTC/DISCN :

blank

02

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 12.5 mg

Price Per Pack (Euro) : 259.72

Published in :

Country : Norway

RX/OTC/DISCN :

blank

03

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 25 mg

Price Per Pack (Euro) : 33.077

Published in :

Country : Norway

RX/OTC/DISCN :

blank

04

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 25 mg

Price Per Pack (Euro) : 89.738

Published in :

Country : Norway

RX/OTC/DISCN :

blank

05

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 25 mg

Price Per Pack (Euro) : 259.72

Published in :

Country : Norway

RX/OTC/DISCN :

blank

06

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Japan
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 25 mg

Price Per Pack (Euro) : 259.72

Published in :

Country : Norway

RX/OTC/DISCN :

blank

07

Brand Name : Moventig

Country
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Country
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Filmtable

Dosage Strength : 12.5mg

Price Per Pack (Euro) : 76.13

Published in :

Country : Switzerland

RX/OTC/DISCN : Class B

blank

08

Brand Name : Moventig

Country
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Country
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Filmtable

Dosage Strength : 25mg

Price Per Pack (Euro) : 76.13

Published in :

Country : Switzerland

RX/OTC/DISCN : Class B

blank

09

Brand Name : Moventig

Country
arrow
AGGSpend
Not Confirmed

Brand Name : Moventig

Country
arrow
AGGSpend
Not Confirmed

Naloxegol Oxalate

Dosage Form : Filmtable

Dosage Strength : 25mg

Price Per Pack (Euro) : 226.69

Published in :

Country : Switzerland

RX/OTC/DISCN : Class B

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1354744-91-4 / Naloxegol Oxalate API manufacturers, exporters & distributors?

Naloxegol Oxalate manufacturers, exporters & distributors 1

19

PharmaCompass offers a list of Naloxegol Oxalate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naloxegol Oxalate manufacturer or Naloxegol Oxalate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naloxegol Oxalate manufacturer or Naloxegol Oxalate supplier.

PharmaCompass also assists you with knowing the Naloxegol Oxalate API Price utilized in the formulation of products. Naloxegol Oxalate API Price is not always fixed or binding as the Naloxegol Oxalate Price is obtained through a variety of data sources. The Naloxegol Oxalate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Naloxegol Oxalate

Synonyms

1354744-91-4, Nktr-118 oxalate, Naloxegol (oxalate), Naloxegol oxalate [usan], Az13337019 oxalate, Az-13337019 oxalate

Cas Number

1354744-91-4

Unique Ingredient Identifier (UNII)

65I14TNM33

Naloxegol Oxalate Manufacturers

A Naloxegol Oxalate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naloxegol Oxalate, including repackagers and relabelers. The FDA regulates Naloxegol Oxalate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naloxegol Oxalate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Naloxegol Oxalate Suppliers

A Naloxegol Oxalate supplier is an individual or a company that provides Naloxegol Oxalate active pharmaceutical ingredient (API) or Naloxegol Oxalate finished formulations upon request. The Naloxegol Oxalate suppliers may include Naloxegol Oxalate API manufacturers, exporters, distributors and traders.

click here to find a list of Naloxegol Oxalate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Naloxegol Oxalate USDMF

A Naloxegol Oxalate DMF (Drug Master File) is a document detailing the whole manufacturing process of Naloxegol Oxalate active pharmaceutical ingredient (API) in detail. Different forms of Naloxegol Oxalate DMFs exist exist since differing nations have different regulations, such as Naloxegol Oxalate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Naloxegol Oxalate DMF submitted to regulatory agencies in the US is known as a USDMF. Naloxegol Oxalate USDMF includes data on Naloxegol Oxalate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Naloxegol Oxalate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Naloxegol Oxalate suppliers with USDMF on PharmaCompass.

Naloxegol Oxalate WC

A Naloxegol Oxalate written confirmation (Naloxegol Oxalate WC) is an official document issued by a regulatory agency to a Naloxegol Oxalate manufacturer, verifying that the manufacturing facility of a Naloxegol Oxalate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Naloxegol Oxalate APIs or Naloxegol Oxalate finished pharmaceutical products to another nation, regulatory agencies frequently require a Naloxegol Oxalate WC (written confirmation) as part of the regulatory process.

click here to find a list of Naloxegol Oxalate suppliers with Written Confirmation (WC) on PharmaCompass.

Naloxegol Oxalate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Naloxegol Oxalate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Naloxegol Oxalate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Naloxegol Oxalate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Naloxegol Oxalate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Naloxegol Oxalate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Naloxegol Oxalate suppliers with NDC on PharmaCompass.

Naloxegol Oxalate GMP

Naloxegol Oxalate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Naloxegol Oxalate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naloxegol Oxalate GMP manufacturer or Naloxegol Oxalate GMP API supplier for your needs.

Naloxegol Oxalate CoA

A Naloxegol Oxalate CoA (Certificate of Analysis) is a formal document that attests to Naloxegol Oxalate's compliance with Naloxegol Oxalate specifications and serves as a tool for batch-level quality control.

Naloxegol Oxalate CoA mostly includes findings from lab analyses of a specific batch. For each Naloxegol Oxalate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Naloxegol Oxalate may be tested according to a variety of international standards, such as European Pharmacopoeia (Naloxegol Oxalate EP), Naloxegol Oxalate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naloxegol Oxalate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty